35 results on '"Canivet, Clémence M."'
Search Results
2. Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests
3. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients
4. Associations between perfluoroalkyl substances and the severity of non-alcoholic fatty liver disease
5. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications
6. Reliability Criteria of Two-Dimensional Shear Wave Elastography: Analysis of 4277 Measurements in 788 Patients
7. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver
8. The mid-infrared spectroscopy: A novel non-invasive diagnostic tool for NASH diagnosis in severe obesity
9. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
10. Immunoglobulin G4-associated autoimmune hepatitis may be found in Western countries
11. The Differential Expression of Cide Family Members is Associated with Nafld Progression from Steatosis to Steatohepatitis
12. Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients.
13. Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients
14. WED-224 Screening for liver fibrosis in tertiary care using automatic calculation of FIB4 in patients at-risk of diabetes
15. THU-503 Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease (MASLD): multicenter study comparing patients with or without underlying cirrhosis
16. OS-054 Validation of the Baveno VII ‘rule of 5’ in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease
17. OS-053 Screening candidates for therapeutic trials in MASH: choose the right non-invasive test for the diagnostic target considered
18. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
19. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
20. Severe Vitamin D Deficiency May be an Additional Cofactor for the Occurrence of Alcoholic Steatohepatitis
21. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.
22. SAT-427 - Practical diagnosis of cirrhosis by liver specialists in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests
23. SAT-419 - Which screening of advanced liver fibrosis in NAFLD?
24. Acute hepatitis B in pregnancy with surprisingly rapid clearance of serum HBs antigen associated with a favourable outcome
25. Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.
26. No association between binge eating disorder and severity of non‐alcoholic fatty liver disease in severely obese patients.
27. Nonalcoholic steatohepatitis cirrhosis and type 1 refractory celiac disease: More than a fortuitous association?
28. Sudden severe jaundice with high fever in a young woman
29. Investigation of Inherited Chromosomally Integrated Human Herpesvirus-6A+ and -6B+ in a Patient with Ulipristal Acetate-Induced Fulminant Hepatic Failure.
30. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
31. CD44 is a key player in non-alcoholic steatohepatitis.
32. Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
33. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners.
34. Investigation of Inherited Chromosomally Integrated Human Herpesvirus-6A+ and -6B+ in a Patient with Ulipristal Acetate-Induced Fulminant Hepatic Failure.
35. Anti-diabetic drugs and NASH: from current options to promising perspectives.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.